These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

303 related items for PubMed ID: 18387067

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Comparative cost-effectiveness of metformin-based dual therapies associated with risk of cardiovascular diseases among Chinese patients with type 2 diabetes: Evidence from a population-based national cohort in Taiwan.
    Ou HT, Chen YT, Liu YM, Wu JS.
    Diabetes Res Clin Pract; 2016 Jun; 116():14-25. PubMed ID: 27321311
    [Abstract] [Full Text] [Related]

  • 3. A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US.
    St Charles M, Minshall ME, Pandya BJ, Baran RW, Tunis SL.
    Curr Med Res Opin; 2009 Jun; 25(6):1343-53. PubMed ID: 19419339
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in Spain.
    Shearer AT, Bagust A, Ampudia-Blasco FJ, Martínez-Lage Alvarez B, Pérez Escolano I, París G.
    Pharmacoeconomics; 2006 Jun; 24 Suppl 1():49-59. PubMed ID: 16800162
    [Abstract] [Full Text] [Related]

  • 6. Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China.
    Gao L, Zhao FL, Li SC.
    Int J Technol Assess Health Care; 2012 Oct; 28(4):436-44. PubMed ID: 23006540
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus from a german statutory healthcare perspective.
    Neeser K, Lübben G, Siebert U, Schramm W.
    Pharmacoeconomics; 2004 Oct; 22(5):321-41. PubMed ID: 15061682
    [Abstract] [Full Text] [Related]

  • 10. PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK.
    Valentine WJ, Bottomley JM, Palmer AJ, Brändle M, Foos V, Williams R, Dormandy JA, Yates J, Tan MH, Massi-Benedetti M, PROactive Study Group.
    Diabet Med; 2007 Sep; 24(9):982-1002. PubMed ID: 17593245
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Long-Term Cost-Effectiveness of Insulin Glargine Versus Neutral Protamine Hagedorn Insulin for Type 2 Diabetes in Thailand.
    Permsuwan U, Chaiyakunapruk N, Dilokthornsakul P, Thavorn K, Saokaew S.
    Appl Health Econ Health Policy; 2016 Jun; 14(3):281-92. PubMed ID: 26961276
    [Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness of rosiglitazone combination therapy for the treatment of type 2 diabetes mellitus in the UK.
    Beale S, Bagust A, Shearer AT, Martin A, Hulme L.
    Pharmacoeconomics; 2006 Jun; 24 Suppl 1():21-34. PubMed ID: 16800160
    [Abstract] [Full Text] [Related]

  • 16. Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation.
    Czoski-Murray C, Warren E, Chilcott J, Beverley C, Psyllaki MA, Cowan J.
    Health Technol Assess; 2004 Apr; 8(13):iii, ix-x, 1-91. PubMed ID: 15038907
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A retrospective cohort study of economic outcomes and adherence to monotherapy with metformin, pioglitazone, or a sulfonylurea among patients with type 2 diabetes mellitus in the United States from 2003 to 2005.
    Hansen RA, Farley JF, Droege M, Maciejewski ML.
    Clin Ther; 2010 Jul; 32(7):1308-19. PubMed ID: 20678679
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.